APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Receptor Superfamily Member 9

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174043760319 December 2025187 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Receptor Superfamily Member 9 Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Receptor Superfamily Member 9 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Receptor Superfamily Member 9 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tumor Necrosis Factor Receptor Superfamily Member 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Receptor Superfamily Member 9 include Eli Lilly and Co, Pfizer Inc, Pieris Pharmaceuticals Inc, MacroGenics Inc, Juno Therapeutics Inc, BioInvent International AB, Apogenix GmbH, Alligator Bioscience AB and Agenus Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Necrosis Factor Receptor Superfamily Member 9 and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Necrosis Factor Receptor Superfamily Member 9 revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Tumor Necrosis Factor Receptor Superfamily Member 9 market size, projected growth trends, production technologies, key applications, and end-use industries.

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Company

Eli Lilly and Co

Pfizer Inc

Pieris Pharmaceuticals Inc

MacroGenics Inc

Juno Therapeutics Inc

BioInvent International AB

Apogenix GmbH

Alligator Bioscience AB

Agenus Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Type

Ultra-41BBL

PRS-342

ISAS-01

EU-101

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Application

Gastric Cancer

Lymphoma

Cervical Cancer

Bladder Cancer

Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 9.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Tumor Necrosis Factor Receptor Superfamily Member 9 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumor Necrosis Factor Receptor Superfamily Member 9 industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 9 companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumor Necrosis Factor Receptor Superfamily Member 9revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Ultra-41BBL Table 3. Key Players of PRS-342 Table 4. Key Players of ISAS-01 Table 3. Key Players of EU-101 Table 4. Key Players of Others Table 5. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Gastric Cancer Table 7. Key Players of Lymphoma Table 8. Key Players of Cervical Cancer Table 9. Key Players of Bladder Cancer Table 10. Key Players of Others Table 11. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2021-2026) Table 14. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2027-2032) Table 16. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends Table 17. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers Table 18. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges Table 19. Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints Table 20. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Company (US$ Million) & (2021-2026) Table 21. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Company (2021-2026) Table 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Key Company Head Office and Area Served Table 24. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company, Product Type & Application Table 25. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Establishment Date Table 26. Global Company Market Concentration Ratio (CR5 and HHI) Table 27. Global Tumor Necrosis Factor Receptor Superfamily Member 9 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 28. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 30. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 31. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2021-2026) Table 32. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2027-2032) Table 33. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 35. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 36. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2021-2026) Table 37. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2027-2032) Table 38. Eli Lilly and Co Company Information Table 39. Eli Lilly and Co Business Overview Table 40. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 42. Eli Lilly and Co Recent Development Table 43. Pfizer Inc Company Information Table 44. Pfizer Inc Business Overview Table 45. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 47. Pfizer Inc Recent Development Table 48. Pieris Pharmaceuticals Inc Company Information Table 49. Pieris Pharmaceuticals Inc Business Overview Table 50. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 52. Pieris Pharmaceuticals Inc Recent Development Table 53. MacroGenics Inc Company Information Table 54. MacroGenics Inc Business Overview Table 55. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 57. MacroGenics Inc Recent Development Table 58. Juno Therapeutics Inc Company Information Table 59. Juno Therapeutics Inc Business Overview Table 60. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 62. Juno Therapeutics Inc Recent Development Table 63. BioInvent International AB Company Information Table 64. BioInvent International AB Business Overview Table 65. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 67. BioInvent International AB Recent Development Table 68. Apogenix GmbH Company Information Table 69. Apogenix GmbH Business Overview Table 70. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 72. Apogenix GmbH Recent Development Table 73. Alligator Bioscience AB Company Information Table 74. Alligator Bioscience AB Business Overview Table 75. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 77. Alligator Bioscience AB Recent Development Table 78. Agenus Inc Company Information Table 79. Agenus Inc Business Overview Table 80. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio Table 82. Agenus Inc Recent Development Table 83. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 84. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 85. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 86. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 87. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) Table 89. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) Table 90. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 91. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 92. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 93. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 94. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) Table 96. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) Table 97. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 98. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 99. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 100. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 101. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 102. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 103. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 104. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 105. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) Table 107. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) Table 108. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US$ Million) Table 109. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032) & (US$ Million) Table 110. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US$ Million) Table 111. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032) & (US$ Million) Table 112. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) Table 114. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Receptor Superfamily Member 9 Product Image Figure 2. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type: 2025 VS 2032 Figure 4. Ultra-41BBL Image Figure 5. PRS-342 Image Figure 6. ISAS-01 Image Figure 7. EU-101 Image Figure 8. Others Image Figure 9. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application: 2025 VS 2032 Figure 11. Gastric Cancer Image Figure 12. Lymphoma Image Figure 13. Cervical Cancer Image Figure 14. Bladder Cancer Image Figure 15. Others Image Figure 16. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 18. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region: 2025 VS 2032 Figure 19. Years Considered Figure 20. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Players in 2025 Figure 21. Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 9 Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2021-2032) Figure 25. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2021-2032) Figure 27. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 28. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032) Figure 29. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032) Figure 30. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 31. United States Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 32. Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 33. Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 34. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 35. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032) Figure 36. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032) Figure 37. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 38. Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 39. France Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 40. U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 41. Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 42. Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 43. Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 44. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 45. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032) Figure 46. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032) Figure 47. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 48. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032) Figure 49. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032) Figure 50. Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 51. Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 52. South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 53. Taiwan Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 54. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 55. India Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 56. Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032) Figure 59. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032) Figure 60. South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032) Figure 61. Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 62. South Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 63. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 64. Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 65. Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 66. UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 67. Egypt Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 68. Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032) & (US$ Million) Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Ultra-41BBL
  • PRS-342
  • ISAS-01
  • EU-101
  • Others
Applications
  • Gastric Cancer
  • Lymphoma
  • Cervical Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Eli Lilly and Co
  • Pfizer Inc
  • Pieris Pharmaceuticals Inc
  • MacroGenics Inc
  • Juno Therapeutics Inc
  • BioInvent International AB
  • Apogenix GmbH
  • Alligator Bioscience AB
  • Agenus Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Ultra-41BBL
  5. 1.2.3 PRS-342
  6. 1.2.4 ISAS-01
  7. 1.2.5 EU-101
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Gastric Cancer
  12. 1.3.3 Lymphoma
  13. 1.3.4 Cervical Cancer
  14. 1.3.5 Bladder Cancer
  15. 1.3.6 Others
  16. 1.4 Global Market Growth Prospects
  17. 1.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Growth Trends by Region
  18. 1.5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region: 2021 VS 2025 VS 2032
  19. 1.5.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026)
  20. 1.5.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2027-2032)
  21. 1.6 Assumptions and Limitations
  22. 1.7 Study Goals and Objectives
  23. 1.8 Years Considered
2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Dynamics
  1. 2.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
  2. 2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers
  3. 2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Company (2021-2026)
  2. 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Key Company Head office and Area Served
  4. 3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company, Product Type & Application
  5. 3.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 9 Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Tumor Necrosis Factor Receptor Superfamily Member 9 Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Type
  1. 4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2032)
  3. 4.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Type (2021-2032)
5 Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Application
  1. 5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2032)
  3. 5.3 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Eli Lilly and Co
  2. 6.1.1 Eli Lilly and Co Company Information
  3. 6.1.2 Eli Lilly and Co Business Overview
  4. 6.1.3 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  6. 6.1.5 Eli Lilly and Co Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 Pieris Pharmaceuticals Inc
  14. 6.3.1 Pieris Pharmaceuticals Inc Company Information
  15. 6.3.2 Pieris Pharmaceuticals Inc Business Overview
  16. 6.3.3 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  18. 6.3.5 Pieris Pharmaceuticals Inc Recent Developments
  19. 6.4 MacroGenics Inc
  20. 6.4.1 MacroGenics Inc Company Information
  21. 6.4.2 MacroGenics Inc Business Overview
  22. 6.4.3 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  24. 6.4.5 MacroGenics Inc Recent Developments
  25. 6.5 Juno Therapeutics Inc
  26. 6.5.1 Juno Therapeutics Inc Company Information
  27. 6.5.2 Juno Therapeutics Inc Business Overview
  28. 6.5.3 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  30. 6.5.5 Juno Therapeutics Inc Recent Developments
  31. 6.6 BioInvent International AB
  32. 6.6.1 BioInvent International AB Company Information
  33. 6.6.2 BioInvent International AB Business Overview
  34. 6.6.3 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  36. 6.6.5 BioInvent International AB Recent Developments
  37. 6.7 Apogenix GmbH
  38. 6.7.1 Apogenix GmbH Company Information
  39. 6.7.2 Apogenix GmbH Business Overview
  40. 6.7.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  42. 6.7.5 Apogenix GmbH Recent Developments
  43. 6.8 Alligator Bioscience AB
  44. 6.8.1 Alligator Bioscience AB Company Information
  45. 6.8.2 Alligator Bioscience AB Business Overview
  46. 6.8.3 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  48. 6.8.5 Alligator Bioscience AB Recent Developments
  49. 6.9 Agenus Inc
  50. 6.9.1 Agenus Inc Company Information
  51. 6.9.2 Agenus Inc Business Overview
  52. 6.9.3 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
  54. 6.9.5 Agenus Inc Recent Developments
7 North America
  1. 7.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  2. 7.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  3. 7.2.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026)
  4. 7.2.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032)
  5. 7.2.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032)
  6. 7.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  7. 7.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026)
  8. 7.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032)
  9. 7.3.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032)
  10. 7.4 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
  11. 7.4.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  13. 7.4.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
  14. 7.4.4 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  2. 8.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  3. 8.2.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026)
  4. 8.2.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032)
  5. 8.2.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032)
  6. 8.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  7. 8.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026)
  8. 8.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032)
  9. 8.3.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032)
  10. 8.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
  11. 8.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  13. 8.4.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
  14. 8.4.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  2. 9.2 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  3. 9.2.1 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026)
  4. 9.2.2 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032)
  5. 9.2.3 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032)
  6. 9.3 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  7. 9.3.1 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026)
  8. 9.3.2 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032)
  9. 9.3.3 China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  2. 10.2 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  3. 10.2.1 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026)
  4. 10.2.2 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032)
  5. 10.2.3 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032)
  6. 10.3 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  7. 10.3.1 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026)
  8. 10.3.2 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032)
  9. 10.3.3 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032)
  10. 10.4 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
  11. 10.4.1 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  13. 10.4.3 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
  14. 10.4.4 Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst